• Mogamulizumab-kpkc is available as an injectable emulsion that should be given directly into the vein as a very slow infusion for at least 1 hour.
• Mogamulizumab-kpkc should be given on day one followed by days 8, 15, 22 of the first 28-day cycle. After the first cycle it is given on days 1 and 15 (twice in a 28-day cycle).
• The dose of mogamulizumab-kpkc can be given within two days of the scheduled dose. Suppose a dose is missed, the next dose of mogamulizumab-kpkc can be given immediately and then followed with the next scheduled dose.
• It is dangerous to give mogamulizumab-kpkc just under the skin (subcutaneous) or as a fast injection into the deep vein (intravenous or IV) and therefore should be avoided.
• Patients can be given anti-allergic drugs and fever-reducing medications during subsequent infusions of mogamulizumab-kpkc if any side effect occurred when it was given the first time.
• The contents of mogamulizumab-kpkc should be transferred into an intravenous bag containing 0.9% sodium chloride to arrive at a final concentration of 1 mg/ ml to 3.0 mg/ ml.
• Gently invert the intravenous bag containing the diluted solution to ensure proper mixing without shaking.
• Do not mix mogamulizumab-kpkc with other drugs and always give mogamulizumab-kpkc through a separate IV line to avoid reactions between drugs.
• The dose of mogamulizumab-kpkc and the required number of vials needed to prepare the infusion must be calculated based on the individual body weight.
• The dose of mogamulizumab-kpkc can be reduced or modified according to the occurrence of side effects. The infusion rate of mogamulizumab-kpkc should be reduced by a minimum of 50 % when the treatment is started again after the side effects are under control.
• The treatment with mogamulizumab-kpkc can either be temporarily stopped or permanently discontinued based on the severity of the side effects, and the patients must be treated appropriately to reduce the impact caused by the side effects.
• Allergic to mogamulizumab-kpkc
• History of skin disorders
• Pregnancy
• Children under 18 years
Caution is required when giving to patients who are-
• Breastfeeding
• With a history of autoimmune disease (Immune system attacks own cells by mistake)
• Weak immunity
• Mogamulizumab-kpkc should be given on day one followed by days 8, 15, 22 of the first 28-day cycle. After the first cycle it is given on days 1 and 15 (twice in a 28-day cycle).
• The dose of mogamulizumab-kpkc can be given within two days of the scheduled dose. Suppose a dose is missed, the next dose of mogamulizumab-kpkc can be given immediately and then followed with the next scheduled dose.
• It is dangerous to give mogamulizumab-kpkc just under the skin (subcutaneous) or as a fast injection into the deep vein (intravenous or IV) and therefore should be avoided.
• Patients can be given anti-allergic drugs and fever-reducing medications during subsequent infusions of mogamulizumab-kpkc if any side effect occurred when it was given the first time.
• The contents of mogamulizumab-kpkc should be transferred into an intravenous bag containing 0.9% sodium chloride to arrive at a final concentration of 1 mg/ ml to 3.0 mg/ ml.
• Gently invert the intravenous bag containing the diluted solution to ensure proper mixing without shaking.
• Do not mix mogamulizumab-kpkc with other drugs and always give mogamulizumab-kpkc through a separate IV line to avoid reactions between drugs.
Dosage & When it is to be taken
• The recommended dose of mogamulizumab-kpkc is 1 mg/kg body weight given slowly for at least 1-hour duration in patients who never show any disease progression or when the treatment with the drug does not result in intolerable toxicity.• The dose of mogamulizumab-kpkc and the required number of vials needed to prepare the infusion must be calculated based on the individual body weight.
• The dose of mogamulizumab-kpkc can be reduced or modified according to the occurrence of side effects. The infusion rate of mogamulizumab-kpkc should be reduced by a minimum of 50 % when the treatment is started again after the side effects are under control.
• The treatment with mogamulizumab-kpkc can either be temporarily stopped or permanently discontinued based on the severity of the side effects, and the patients must be treated appropriately to reduce the impact caused by the side effects.
When it is not to be taken (Contraindications)
Mogamulizumab-kpkc should not be used in patients with-• Allergic to mogamulizumab-kpkc
• History of skin disorders
• Pregnancy
• Children under 18 years
Caution is required when giving to patients who are-
• Breastfeeding
• With a history of autoimmune disease (Immune system attacks own cells by mistake)
• Weak immunity
